Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Soichiro Morinaga

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-1551-1837; OpenAlex author ID A5019304753, A5024304106. Sources: OpenAlex.

Their work

Papers
61 (first author 4, last author 31)
Trials
0
Grants
0
Labs led
1
Collaborators
116
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 7 papers · 2016: 7 papers · 2017: 3 papers · 2018: 5 papers · 2019: 2 papers · 2020: 7 papers · 2021: 2 papers · 2022: 6 papers · 2023: 5 papers · 2024: 6 papers · 2025: 5 papers · 2026: 2 papers

Papers 50 of 61

  1. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  2. Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19380-z↗
  3. A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival. Co-author DOI 10.1016/j.biomaterials.2024.122838↗
  4. Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment. Co-author DOI 10.1016/j.xpro.2024.103539↗
  5. Integrated cell atlas and tumoroids chart pancreatic cancer therapeutic targets Co-author DOI 10.1101/2025.09.30.679518↗
  6. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18186-9↗
  7. Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer. Last author DOI 10.21873/anticanres.17804↗
  8. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  9. Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic ca… Last author DOI 10.1007/s00423-024-03512-8↗
  10. Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant… Last author DOI 10.1186/s12885-024-13244-z↗
  11. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Last author DOI 10.21873/anticanres.16805↗
  12. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy. Last author DOI 10.21873/anticanres.16970↗
  13. Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatec… Last author DOI 10.21873/anticanres.17286↗
  14. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Co-author DOI 10.1002/jhbp.1353↗
  15. Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. Co-author DOI 10.1016/j.celrep.2023.113420↗
  16. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. Last author DOI 10.1186/s12957-023-03141-3↗
  17. Carbon Ion Radiotherapy Versus Perioperative Adjuvant Chemotherapy and Curative Surgery for Resectable Pancreatic Cancer. Last author DOI 10.21873/anticanres.16222↗
  18. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Last author DOI 10.21873/anticanres.16327↗
  19. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  20. Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00423-022-02481-0↗
  21. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  22. Reconstructing cell interactions and state trajectories in pancreatic cancer stromal tumoroids Co-author DOI 10.1101/2022.02.14.480334↗
  23. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Co-author DOI 10.21873/anticanres.15547↗
  24. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Co-author DOI 10.3892/ol.2022.13495↗
  25. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. First author DOI 10.1097/mpa.0000000000001702↗
  26. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Co-author DOI 10.1111/cas.14914↗
  27. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.10.031↗
  28. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the … Co-author DOI 10.1097/mpa.0000000000001692↗
  29. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  30. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Co-author DOI 10.1186/s12885-020-07698-0↗
  31. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… Last author DOI 10.21873/invivo.11780↗
  32. The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer. Last author DOI 10.21873/invivo.11931↗
  33. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… Last author DOI 10.4103/jcrt.jcrt_440_18↗
  34. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-53801-2↗
  35. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Last author DOI 10.7150/jca.28660↗
  36. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
  37. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Last author DOI 10.21873/anticanres.12801↗
  38. Safety and feasibility of enhanced recovery after surgery in the patients underwent distal pancreatectomy for pancreatic cancer. Last author DOI 10.4103/0973-1482.183186↗
  39. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy. Last author DOI 10.4103/0973-1482.194927↗
  40. [Evaluation of Body Temperature during Pancreaticoduodenectomy for Pancreatic Cancer in Elderly Patients Aged over 75 Years Old]. Last author PMID 29483421↗
  41. Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherap… Last author DOI 10.3892/ol.2017.5935↗
  42. Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant … Last author DOI 10.3892/ol.2017.6220↗
  43. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemoth… Last author DOI 10.3892/ol.2017.6295↗
  44. Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Co-author DOI 10.1016/j.pan.2016.07.007↗
  45. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
  46. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adju… Co-author PMID 26977002↗
  47. Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer… First author PMID 27127159↗
  48. The Surgical Apgar Score Is an Independent Prognostic Factor in Patients with Pancreatic Cancer Undergoing Pancreatoduodenectomy Followed by Adjuvant Chemother… Last author PMID 27127164↗
  49. [A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. Last author PMID 27760963↗
  50. [Safety and Feasibility of Pancreatic Surgery for Pancreatic Cancer in Elderly Patients]. Last author PMID 28133043↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 34 shared papers, 2014–2026 · strength 3.70
  2. Masaaki Murakawa · 34 shared papers, 2014–2026 · strength 3.51
  3. Naoto Yamamoto · 26 shared papers, 2012–2025 · strength 2.84
  4. Shinnosuke Kawahara · 11 shared papers, 2022–2026 · strength 1.95
  5. Satoshi Kobayashi · 19 shared papers, 2014–2026 · strength 1.86
  6. Toru Aoyama · 25 shared papers, 2014–2025 · strength 1.85
  7. Yohei Miyagi · 16 shared papers, 2012–2026 · strength 1.85
  8. Yuto Kamioka · 10 shared papers, 2020–2026 · strength 1.69
  9. Manabu Morimoto · 24 shared papers, 2014–2023 · strength 1.66
  10. Mariko Kamiya · 10 shared papers, 2018–2026 · strength 1.50
  11. Takashi Oshima · 14 shared papers, 2015–2024 · strength 1.20
  12. Katsuhiko Uesaka · 10 shared papers, 2016–2026 · strength 1.11
  13. Hirochika Toyama · 8 shared papers, 2019–2026 · strength 1.00
  14. Hiroshi Tamagawa · 11 shared papers, 2012–2024 · strength 0.98
  15. Akira Fukutomi · 8 shared papers, 2016–2026 · strength 0.88
  16. Masayuki Ohtsuka · 4 shared papers, 2023–2025 · strength 0.75
  17. Toru Aoyama · 5 shared papers, 2016–2024 · strength 0.74
  18. Shinichiro Takahashi · 6 shared papers, 2019–2024 · strength 0.73
  19. Yukiyasu Okamura · 6 shared papers, 2016–2026 · strength 0.69
  20. Hideki Taniguchi · 4 shared papers, 2018–2025 · strength 0.67
  21. Shunsuke Tabe · 3 shared papers, 2023–2025 · strength 0.59
  22. Kenta Takeuchi · 3 shared papers, 2023–2025 · strength 0.59
  23. Atsushi Miyamoto · 4 shared papers, 2020–2026 · strength 0.54
  24. Narikazu Boku · 5 shared papers, 2016–2026 · strength 0.53
  25. Shoji Nakamori · 6 shared papers, 2016–2022 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.